1.Lenders JW, Eisenhofer G, Mannelli M, Pacak K 2005 Phaeochromocytoma. Lancet 366:665-675

2.Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, Eisenhofer G 2002 Biochemical diagnosis of pheochromocytoma: which test is best? Jama 287:1427-1434

3.Eisenhofer G, Lenders JW, Pacak K 2004 Biochemical diagnosis of pheochromocytoma. Front Horm Res 31:76-106

4.Elder EE, Elder G, Larsson C 2005 Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. J Surg Oncol 89:193-201

5.Manger WM, Gifford RW 2002 Pheochromocytoma. J Clin Hypertens 4:62-72

6.Bravo E 1994 Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev 15:356-368

7.Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A 2000 A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85:637-644.

8.Whalen RK, Althausen AF, Daniels GH 1992 Extra-adrenal pheochromocytoma. J Urol 147:1-10.

9.O'Riordain DS, Young WF, Jr., Grant CS, Carney JA, van Heerden JA 1996 Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg 20:916-921

10.Remine W, Chong G, van Heerden J, Sheps S, Harrison EJ 1974 Current management of pheochromocytoma. Ann Surg 179:740-748

11.Klingler HC, Klingler PJ, Martin JK, Jr., Smallridge RC, Smith SL, Hinder RA 2001 Pheochromocytoma. Urology 57:1025-1032

12.Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS 2001 Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134:315-329.

13.Manger WM, Gifford RW 1996 Clinical and Experimental Pheochromocytoma. 2nd ed. Cambridge, MA: Blackwell Science

14.Streeten DH, Anderson GH, Jr. 1996 Mechanisms of orthostatic hypotension and tachycardia in patients with pheochromocytoma. Am J Hypertens 9:760-769

15.Bravo EL, Gifford RW, Jr. 1993 Pheochromocytoma. Endocrinol Metab Clin North Am 22:329-341

16.Bravo EL, Tagle R 2003 Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24:539-553

17.Manger W, Gifford R 1996 Clinical and Experimental Pheochromocytoma. Blackwell Science, Cambridge, Massachusetts.

18.Ram CV, Fierro-Carrion GA 1995 Pheochromocytoma. Semin Nephrol 15:126-137.

19.Steen RE, Kapelrud H, Haug E, Frey H 1991 In vivo and in vitro inhibition by ketoconazole of ACTH secretion from a human thymic carcinoid tumour. Acta Endocrinol (Copenh) 125:331-334

20.Bouloux PG, Fakeeh M 1995 Investigation of phaeochromocytoma. Clin Endocrinol (Oxf) 43:657-664.

21.Kuchel O 1985 Pseudopheochromocytoma. Hypertension 7:151-158

22.Kuchel O 2004 New Insights Into Pseudopheochromocytoma and Emotionally Provoked Hypertension. In: Mansoor GA ed. Secondary Hypertension. Totowa: Humana Press; in press

23.Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C 2002 Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459-1466

24.Pacak K, Ilias I, Adams KT, Eisenhofer G 2005 Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med 257:60-68

25.Mulligan L, Eng C, Healey C, Clayton D, Kwok J, Gardner E, Ponder M, Frilling A, Jackson C, Lehnert H, Neumann H, Thibodeau S, Ponder B 1994 Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genetics 6:70-74

26.Schuffenecker I, Billaud M, Calender A, Chambe B, Ginet N, Calmettes C, Modigliani E, Lenoir GM 1994 RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 3:1939-1943.

27.Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA, Jr., Goodfellow PJ, Donis-Keller H 1994 Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 91:1579-1583.

28.Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A, et al. 1994 Point mutation within the tyrosine kinase domain of the RET proto- oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3:237-241.

29.Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJ, Gagel RF, Takai SI, Noll WW, Fink M, et al. 1995 Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 238:343-346.

30.Karsdorp N, Elderson A, Wittebol-Post D, Hene RJ, Vos J, Feldberg MA, van Gils AP, Jansen-Schillhorn van Veen JM, Vroom TM, Hoppener JW, et al. 1994 Von Hippel-Lindau disease: new strategies in early detection and treatment. Am J Med 97:158-168.

31.Koch CA, Huang SC, Zhuang Z, Stolle C, Azumi N, Chrousos GP, Vortmeyer AO, Pacak K 2002 Somatic VHL gene deletion and point mutation in MEN 2A-associated pheochromocytoma. Oncogene 21:479-482

32.Lamiell JM, Salazar FG, Hsia YE 1989 von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore) 68:1-29.

33.Linehan W, Lerman M, Zbar B 1995 Identification of the VHL Gene: Its Role in Renal Carcinoma. JAMA 273:564-570

34.Brauch H, Kishida T, Glavac D, Chen F, Pausch F, Hofler H, Latif F, Lerman M, Zbar B, Neumann H 1995 Von Hippel Lindau (VHL) disease with pheochromocytoma in the Black forest region of Germany: evidence for a founder effect. Hum Genet 95:551-556

35.Huson SM, Compston DA, Clark P, Harper PS 1989 A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 26:704-711.

36.Riccardi VM 1991 Neurofibromatosis: past, present, and future. N Engl J Med 324:1283-1285.

37.Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Skoldberg F, Husebye ES, Eng C, Maher ER 2001 Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69:49-54

38.Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, Richard CW, 3rd, Cornelisse CJ, Devilee P, Devlin B 2000 Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287:848-851.

39.Baysal BE, Willett-Brozick JE, Lawrence EC, Drovdlic CM, Savul SA, McLeod DR, Yee HA, Brackmann DE, Slattery WH, 3rd, Myers EN, Ferrell RE, Rubinstein WS 2002 Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 39:178-183

40.Schiavi F, Boedeker CC, Bausch B, Peczkowska M, Gomez CF, Strassburg T, Pawlu C, Buchta M, Salzmann M, Hoffmann MM, Berlis A, Brink I, Cybulla M, Muresan M, Walter MA, Forrer F, Valimaki M, Kawecki A, Szutkowski Z, Schipper J, Walz MK, Pigny P, Bauters C, Willet-Brozick JE, Baysal BE, Januszewicz A, Eng C, Opocher G, Neumann HP 2005 Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. Jama 294:2057-2063

41.Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A, Niccoli-Sire P, Richard S, Rohmer V, Sadoul JL, Strompf L, Schlumberger M, Bertagna X, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP 2005 Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23:8812-8818

42.Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF, Jeunemaitre X 2003 Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63:5615-5621

43.Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C 2004 Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. Jama 292:943-951

44.Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PL, Elston M, Gimm O, Henley D, Herman P, Murday V, Niccoli-Sire P, Pasieka JL, Rohmer V, Tucker K, Jeunemaitre X, Marsh DJ, Plouin PF, Robinson BG 2005 Clinical presentation and penetrance of Pheochromocytoma/ Paraganglioma syndromes. J Clin Endocrinol Metab

45.Young AL, Baysal BE, Deb A, Young WF, Jr. 2002 Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. J Clin Endocrinol Metab 87:4101-4105

46.Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, Pacak K 2006 High Frequency of SDHB Germline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing. J Clin Endocrinol Metab 91:4505-4509

47.Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL 2003 Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst 95:1196-1204

48.Eisenhofer G 1994 Plasma normetanephrine for examination of extraneuronal uptake and metabolism of noradrenaline in rats. Naunyn Schmiedebergs Arch Pharmacol 349:259-269

49.Eisenhofer G 2001 The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 91:35-62

50.Eisenhofer G 2003 Editorial: biochemical diagnosis of pheochromocytoma--is it time to switch to plasma-free metanephrines? J Clin Endocrinol Metab 88:550-552

51.Eisenhofer G, Goldstein DS, Kopin IJ, Crout JR 2003 Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocr Pathol:'in press'

52.Eisenhofer G, Huynh TT, Hiroi M, Pacak K 2001 Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev Endocr Metab Disord 2:297-311

53.Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh TT, Hiremagalur B, Ellingson T, Duddempudi S, Eijsbouts A, Lenders JW 1998 Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 83:2175-2185

54.Eisenhofer G, Lenders J, Linehan W, Walther M, Goldstein D, Keiser H 1999 Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 340:1872-1879

55.Eisenhofer G, Lenders JW, Pacak K 2002 Choice of biochemical test for diagnosis of pheochromocytoma: validation of plasma metanephrines. Curr Hypertens Rep 4:250-255

56.Sawka AM, Gafni A, Thabane L, Young WF, Jr. 2004 The economic implications of three biochemical screening algorithms for pheochromocytoma. J Clin Endocrinol Metab 89:2859-2866

57.Sawka AM, Jaeschke R, Singh RJ, Young WF, Jr. 2003 A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 88:553-558

58.Unger N, Pitt C, Schmidt IL, Walz MK, Schmid KW, Philipp T, Mann K, Petersenn S 2006 Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol 154:409-417

59.Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, Pacak K 2003 Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 88:2656-2666

60.Eisenhofer G, Huysmans F, Pacak K, Walther MM, Sweep FC, Lenders JW 2005 Plasma metanephrines in renal failure. Kidney Int 67:668-677

61.Eisenhofer G, Goldstein DS, Sullivan P, Csako G, Brouwers FM, Lai EW, Adams KT, Pacak K 2005 Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 90:2086-2075

62.Ilias I, Pacak K 2004 Current approaches and recommended algorithm for the diagnostic localization of pheohcromocytoma. J Clin Endocrinol Metab 89

63.Furuta N, Kiyota H, Yoshigoe F, Hasegawa N, Ohishi Y 1999 Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol 6:119-124

64.van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP, Bosman FT, Kwekkeboom DJ 2001 [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 86:685-693.

65.Ilias I, Shulkin B, Pacak K 2005 New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends Endocrinol Metab 16:66-72

66.Pacak K, Eisenhofer G, Goldstein DS 2004 Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 25:568-580

67.Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS 2001 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38:6-8.

68.Ilias I, Yu J, Carrasquillo JA, Chen CC, Eisenhofer G, Whatley M, McElroy B, Pacak K 2003 Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 88:4083-4087

69.Hoegerle S, Ghanem N, Altehoefer C, Schipper J, Brink I, Moser E, Neumann HP 2003 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 30:689-694

70.Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, Reincke M, Moser E, Neumann HP 2002 Pheochromocytomas: detection with 18F DOPA whole body PET--initial results. Radiology 222:507-512

71.Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC 1999 Pheochromocytomas: Imaging with 2-[Fluorine-18]fluoro-2-deoxy-D-glucose PET. Nucl Med 212:35-41

72.Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS, Rosenspire KC, Shapiro B, Sisson JC, Kuh lDE 1992 PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med 33:1125-1131

73.Mann GN, Link JM, Pham P, Pickett CA, Byrd DR, Kinahan PE, Krohn KA, Mankoff DA 2006 [(11)C]metahydroxyephedrine and [(18)f]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol 13:187-197

74.Mamede M, Carrasquillo JA, Chen CC, Del Corral P, Whatley M, Ilias I, Ayala A, Pacak K 2006 Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun 27:31-36

75.Pacak K, Keiser H, Eisenhofer G 2005 Pheochromocytoma. In: De Groot LS, Jameson JL eds. Textbook of Endocrinology. 5th ed

76.Brouwers FM, Lenders JW, Eisenhofer G, Pacak K 2003 Pheochromocytoma as an endocrine emergency. Rev Endocr Metab Disord 4:121-128

77.Pacak K, Chrousos GP, Koch CA, Lenders JW, Eisenhofer G 2001 Pheochromocytoma: progress in diagnosis, therapy, and genetics. In: Margioris A, Chrousos GP eds. Adrenal Disorders. 1 ed. Totowa: Humana Press; 479-523

78.Goldstein RE, O'Neill JA, Jr., Holcomb GW, 3rd, Morgan WM, 3rd, Neblett WW, 3rd, Oates JA, Brown N, Nadeau J, Smith B, Page DL, Abumrad NN, Scott HW, Jr. 1999 Clinical experience over 48 years with pheochromocytoma. Ann Surg 229:755-764; discussion 764-756

79.John H, Ziegler WH, Hauri D, Jaeger P 1999 Pheochromocytomas: can malignant potential be predicted? Urology 53:679-683

80.Proye CA, Vix M, Jansson S, Tisell LE, Dralle H, Hiller W 1994 "The" pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist? World J Surg 18:467-472.

81.Yu J, Pacak K 2002 Metastatic pheochromocytoma. Endocrinologist 12:291-299

82.Mundschenk J, Lehnert H 1998 Malignant pheochromocytoma. Exp Clin Endocrinol Diabetes 106:373-376

83.Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR 1988 Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109:267-273

84.Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC 1997 The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 20:648-658

85.Kopf D, Bockisch A, Steinert H, Hahn K, Beyer J, Neumann HP, Hensen J, Lehnert H 1997 Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clin Endocrinol (Oxf) 46:39-44

86.Werbel SS, Ober KP 1995 Pheochromocytoma. Update on diagnosis, localization, and management. Med Clin North Am 79:131-153

87.Calandra RS, Antar MA, Plautz M, Little JA, Martin JM, Johnson GE 1970 Hormonal and metabolic studies in pheochromocytoma. Can Med Assoc J 102:1369-1372

88.Eisenhofer G, Pacak K 2004 Diagnosis of pheochromocytoma. In: Harrison’s Textbook Online